Abstract

SO.21.04

Intravitreal ranibizumab for treatment of macular edema secondary to central retinal vein occlusion – RAVO study

Thomas Kreutzer1, Nicolas Feltgen2, Armin Wolf1, Aris Kollias1, Anselm Kampik1, Siegfried Priglinger3, and the The RAVO Study Group
1Augenklinik, Ludwig-Maximilians-Universität, München, 2Universitäts-Augenklinik Göttingen, Augenklinik, 3Augenklinik, AKH Linz, Linz, Österreich

Objective
Prospective, randomized, multi-centered study to evaluate the effectivness of combined treatment with isovolemic hemodilution and intravitreal ranibizumab injections verus primarily sole isovolemic hemodilution in eyes with macular edema secondary to central retinal vein occlusion (CRVO).
Methods
Sixty patients (2x30) with macular edema secondary to recent CRVO (no longer than 8 weeks) are randomized to either sole isovolemic hemodilution (group I) or combined with initially three monthly intravitreal injections of 0.5mg ranibizumab (group II). In case of failure to treatment after two months group I eyes can also be additionally treated with monthly intravitreal ranibizumab injections. Primary variables are best corrected visual acuity according to ETDRS standards and central retinal thickness measured with OCT.  Secondary parameters are retinal perfusion, complications and injection frequency. Patients are monitored monthly over one year. Decission on reinjection after the initial loading phase is based on reduction of visual acuity by five letters and increase of central retinal thickness by 50m.
Results
So far 20 patients have been recruited for the RAVO study. A detailed presentation of the study protocol and  early results of the interims analysis is planned.
Conclusions
Early results suggest that intravitreal ranibizumab therapy for macular edema secondary to CRVO seems to be a promising treatment option.

Copyright: 2009 Porstmann Kongresse GmbH. All rights reserved. Impressum, Disclaimer.